A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19.

Autor: Liu, Wang-Da1,2 (AUTHOR), Feng, Po-Hao3,4 (AUTHOR), Cheng, Chien-Yu5 (AUTHOR), Chou, Chun-Liang6 (AUTHOR), Lee, Chih-Hsin4,7 (AUTHOR), Lu, Min-Chi8 (AUTHOR), Liu, Po-Yu9 (AUTHOR), Lee, Mei-Hui10 (AUTHOR), Liao, Chun-Hsing11 (AUTHOR), Chen, Mei-Chuan6 (AUTHOR), Chen, Cheng-Pin5 (AUTHOR), Hsu, Shang-Fu6 (AUTHOR), Tzeng, Yu-Tien7 (AUTHOR), Lin, Yi-Chun5 (AUTHOR), Ou, Tsong-Yih12 (AUTHOR), Qin, Albert13 (AUTHOR), Tsai, Chan-Yen13 (AUTHOR), Shih, Weichung Joe14 (AUTHOR), Lee, Kang-Yun3,4,15 (AUTHOR) 13258@s.tmu.edu.tw, Sheng, Wang-Huei1,16 (AUTHOR) whsheng@ntu.edu.tw
Zdroj: Infectious Diseases & Therapy. Jul2024, Vol. 13 Issue 7, p1575-1588. 14p.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje